How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.
The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market. This story matters for Finance & Markets readers tracking bond. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. BondNews curates and briefs the finance & markets stories that matter. Our editorial policy →